EGDT gained global adoption after 2001, but later trials showed no survival benefit, exposing its flaws, risks, and poor ...
Although switching is usually safe and well tolerated, physician judgment concerning individual patient requirements must be maintained. The dose of the first- or second-generation β blocker that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback